Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer. Patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.
Prostate Cancer
BIOLOGICAL: CV787 (CG7870)
To determine the safety, tolerability, and the maximum tolerated dose of CG7870 when administered intravenously to patients with progressive metastatic hormone refractory prostate cancer
To evaluate prostate-specific antigen (PSA) response rates, duration of response, and time to disease progression|To evaluate other clinical efficacy responses observed|To evaluate the systemic pharmacokinetics of CG7870 after intravenous administration|To monitor the immune response to CG7870
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer. Patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.